BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Semanteon Capital Management LP

Semanteon Capital Management LP increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 32.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 197,760 shares of the biotechnology company's stock after buying an additional 48,184 shares during the quarter. BioCryst Pharmaceuticals comprises 0.8% of Semanteon Capital Management LP's investment portfolio, making the stock its 6th biggest holding. Semanteon Capital Management LP owned about 0.10% of BioCryst Pharmaceuticals worth $1,487,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its holdings in shares of BioCryst Pharmaceuticals by 40.7% in the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock valued at $2,274,000 after buying an additional 86,571 shares during the last quarter. Principal Financial Group Inc. lifted its position in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock worth $3,127,000 after acquiring an additional 375,890 shares during the period. Fisher Asset Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock valued at $25,369,000 after purchasing an additional 481,359 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock valued at $14,890,000 after purchasing an additional 91,998 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock valued at $36,776,000 after purchasing an additional 127,708 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

BCRX has been the topic of a number of analyst reports. JMP Securities reiterated a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Needham & Company LLC lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a report on Monday, January 13th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $15.57.

BioCryst Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ:BCRX traded up $0.02 during trading on Tuesday, hitting $8.07. 3,783,151 shares of the stock were exchanged, compared to its average volume of 2,756,741. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.50. The company has a market cap of $1.69 billion, a PE ratio of -13.23 and a beta of 1.85. The company has a fifty day moving average price of $8.12 and a two-hundred day moving average price of $7.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The business's revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.28 earnings per share. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.